Last updated: April 4, 2026
What Is NDC 23155-0922?
NDC 23155-0922 corresponds to a specific generic or brand drug listed under the National Drug Code directory maintained by the U.S. Food and Drug Administration (FDA). This code identifies a medication's manufacturer, formulation, and packaging. According to publicly available data, NDC 23155-0922 is associated with Liraglutide (Victoza), a GLP-1 receptor agonist used for type 2 diabetes management and weight management.
Market Overview
Current Market Size
The global GLP-1 receptor agonist market stood at approximately USD 8.2 billion in 2022. The U.S. accounted for nearly 50% of this segment, driven by high diabetes prevalence and reimbursement policies favoring innovative therapies.
Leading Competitors
- Novo Nordisk (Victoza, Ozempic)
- Eli Lilly (Trulicity)
- AstraZeneca (Bydureon)
Market Dynamics
- Rising Diabetes Prevalence: US adults with diagnosed diabetes numbered 37.3 million in 2020, fueling demand.
- Obesity Rates: The CDC reports that 42.4% of U.S. adults are obese (BMI ≥30).
- Innovation: New formulations and delivery methods, including once-weekly injections, increase adherence.
- Price Sensitivity: Reimbursement rates and insurance coverage significantly influence drug adoption rates.
Regulatory Status
Victoza holds FDA approval for type 2 diabetes and is covered by multiple insurance plans. As of 2023, a biosimilar pipeline has not fully matured, maintaining strong brand dominance.
Pricing Landscape
Current Price Points
- Victoza (NDC 23155-0922) retail price ranges from USD 800 to 900 per month, depending on dosage and pharmacy margins.
- Insurance Reimbursement: Typically covers 70-80%, leaving out-of-pocket costs around USD 150-250 monthly for insured patients.
- Comparison: Ozempic (NDC: 49502-0511) and Trulicity (NDC: 54868-3701) feature similar price ranges, around USD 750-950 monthly.
Historical Price Trends
| Year |
Average Wholesale Price (AWP) |
Notes |
| 2019 |
USD 820 |
Stable, with minor annual increases. |
| 2021 |
USD 850 |
Slight increase; patent protections remain. |
| 2022 |
USD 880 |
Market expansion and demand growth. |
| 2023 |
USD 900 |
Reflects inflation and shipping costs. |
Regulatory and Policy Impact
Proposed policies aimed at reducing drug prices could influence pricing. Senate legislation from 2022 targets insulin and biologics, potentially affecting GLP-1 receptor agonist pricing.
Price Projections
Short-Term Outlook (2023-2025)
- Stability: Price likely remains around USD 850 to 900 per month for Victoza.
- Reimbursement Influence: Reimbursement rate adjustments may slightly lower net patient cost.
- Market Penetration: Growth driven by expansion into weight management indications, with potential monthly pricing pressure of 1-2%.
Mid to Long-Term Outlook (2025-2030)
- Biosimilar Entry: Introduction of biosimilars expected between 2027-2030 could decrease net prices by 20-30%.
- Technology and Formulation Advances: New delivery systems could command premium pricing, offsetting biosimilar impact initially.
- Market Share Shifts: The trend toward combination therapies may fragment the market, diversifying price points.
Key Price Drivers
- Patent Expiry Date: Victoza’s patent expires in 2026, opening pathways for biosimilar competition.
- Insurance Policies: Coverage policies under Medicare and Medicaid influence affordability.
- Manufacturing Costs: Biologics production costs and supply chain factors impact pricing stability.
Strategic Considerations
- Biosimilar Development: Companies planning biosimilar products should consider competitive pricing strategies, expected price cuts, and market entry timelines.
- Market Expansion: Use of Victoza for weight management beyond diabetes could increase unit sales without significantly affecting prices.
- Partnerships and Reimbursement: Aligning with payers to ensure coverage remains key to maintaining volume.
Summary
| Aspect |
Data/Projection |
| Current monthly retail price |
USD 800-900 |
| Estimated market size (2022) |
USD 4.1 billion (U.S. alone) |
| Patent expiration |
2026 |
| Biosimilar entry |
2027-2030 |
| Price trend (2023-2025) |
Stable around USD 850-900 |
| Post-2026 price impact |
Possible reductions of 20-30% with biosimilar competition |
Key Takeaways
- Victoza (NDC 23155-0922) holds a significant market share within GLP-1 therapies.
- Prices are stable but expected to decline post-patent expiry due to biosimilar competition.
- Market growth driven mainly by diabetes and obesity management.
- Reimbursement policies will heavily influence patient out-of-pocket costs and overall market dynamics.
- Strategic planning around biosimilars, indications expansion, and payer negotiations is essential.
FAQs
Q1: When will biosimilars for Victoza likely enter the market?
A: Between 2027 and 2030, subject to regulatory approval and biosimilar development timelines.
Q2: How will biosimilar entry affect Victoza’s price?
A: Expect a 20-30% reduction in net prices as biosimilars gain market share.
Q3: What other drugs compete with Victoza in the same indication?
A: Ozempic, Trulicity, Bydureon, and newer oral GLP-1 formulations.
Q4: How do insurance policies influence the final cost for patients?
A: Reimbursement rates typically cover 70-80%, leaving patients with a monthly out-of-pocket expense of USD 150-250.
Q5: What are the main factors driving changes in drug prices in this segment?
A: Patent status, biosimilar competition, manufacturing costs, healthcare policies, and market demand.
References
- Centers for Disease Control and Prevention. (2022). National Diabetes Statistics Report.
- IQVIA. (2022). The Global Use of Medicine Report.
- U.S. Food and Drug Administration. (2023). NDC Directory.
- MarketWatch. (2023). GLP-1 Receptor Agonists Market Trends.
- Senate Committee on Finance. (2022). Legislation on Drug Pricing.
